Sleep Medicine
Volume 8, Issue 7 , Pages 695-703, November 2007

Evaluation of autoCPAP devices in home treatment of sleep apnea/hypopnea syndrome

  • J.C. Meurice

      Affiliations

    • Service de Pneumologie, 2 Rue de la Milétrie, CHU de Poitiers, 86000 Poitiers, France
    • Corresponding Author InformationCorresponding author.
  • ,
  • A. Cornette

      Affiliations

    • CHU Nancy, France
  • ,
  • F. Philip-Joet

      Affiliations

    • CHU La Timone, Marseille, France
  • ,
  • J.L. Pepin

      Affiliations

    • CHU Grenoble, France
  • ,
  • P. Escourrou

      Affiliations

    • Hôpital A Béclère, Clamart, France
  • ,
  • P. Ingrand

      Affiliations

    • Département de Biostatistiques Médicales Faculté de Médecine de Poitiers, France
  • ,
  • D. Veale

      Affiliations

    • Centre H Bazire, Grenoble, France
  • ,
  • ANTADIR “PPC” Working Group

Received 21 December 2006; received in revised form 14 March 2007; accepted 15 March 2007.

Abstract 

Background and purpose

Quality of life (QOL) and sleepiness for patients with sleep apnea/hypopnea syndrome (SAHS) might improve with continuous positive airway pressure devices working in auto-adjust mode (autoCPAP) by allowing pressure modulations following patient needs. Clinical comparisons between devices driven by different algorithms are needed.

Methods

We compared the clinical effectiveness of fixed pressure CPAP and four different autoCPAP devices by assessing compliance and QOL (36-item short-form health survey [SF-36]). SAHS patients were randomly allocated to five groups. Polysomnography (PSG) was performed to titrate the effective pressure in the constant CPAP group and evaluate residual apnea/hypopnea index (AHI) under autoCPAP. Follow-up consisted of clinical visits at three and six months by homecare technicians who assessed compliance, symptom scores and SF-36 scores. A laboratory-based PSG using the same CPAP/autoCPAP device as at home was performed at six months.

Results

Eighty-three patients (mean age 56±10 yrs) with mean body mass index (BMI) 30.8±5.3kg/m2 and severe SAHS (mean AHI: 52.3±17.8/h) were included. There were no differences in clinical symptoms or QOL scores, and similar clinical and PSG improvements were seen in all groups. CPAP use was >5h per night, without any significant difference between groups.

Conclusions

AutoCPAP is equally as effective as fixed CPAP for long-term home treatment in severe SAHS patients.

Keywords: Continuous positive airway pressure, AutoCPAP, Compliance, Quality of life, Sleep apnea syndrome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1389-9457(07)00125-6

doi:10.1016/j.sleep.2007.03.019

Sleep Medicine
Volume 8, Issue 7 , Pages 695-703, November 2007